Trials / Terminated
TerminatedNCT00568061
Nitric Oxide in Myocardial Infarction Size
The Effects of Nitric Oxide for Inhalation on Myocardial Infarction Size
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 29 (actual)
- Sponsor
- Mallinckrodt · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess whether or not inhaled nitric oxide can decrease myocardial infarction (MI) size at 48-72 hours in patients presenting with an ST segment elevation MI (STEMI) who undergo successful percutaneous coronary intervention.
Detailed description
The purpose of the trial is to assess whether or not inhaled nitric oxide can decrease myocardial infarction (MI) size as a fraction of left ventricular (LV) size at 48-72 hours in patients presenting with an ST segment elevation MI who undergo successful percutaneous coronary intervention (PCI). The primary endpoint for this study will be myocardial infarction size as a fraction of left ventricular size at 48-72 hours as measured by contrast-enhanced cardiac MRI.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nitric Oxide | Nitric oxide for inhalation |
| DRUG | Placebo | Nitrogen gas (placebo) for inhalation |
Timeline
- Start date
- 2006-06-01
- Primary completion
- 2008-06-01
- Completion
- 2008-06-01
- First posted
- 2007-12-05
- Last updated
- 2019-11-21
- Results posted
- 2010-08-27
Locations
14 sites across 3 countries: United States, Belgium, Canada
Source: ClinicalTrials.gov record NCT00568061. Inclusion in this directory is not an endorsement.